Kintara (KTRA) Net earnings per share growth forecast for next year

Corporate company logo of Kintara Therapeutics (KTRA)

Kintara Therapeutics (KTRA) is valued by physicians for its safe treatment methods for rare brain tumors. The company focuses on low-competition niches, developing agents against severe forms of skin and brain cancer. Patents and FDA orphan drug designations create a robust defensive barrier. The projected change in earnings per share for the coming year confirms these expectations, with the -4.20 level serving as a critical benchmark.

Kintara (KTRA): Net earnings per share growth forecast for next year from 07/04/2022 to 11/17/2026

Summary analytical data breakdowns for Kintara (KTRA)

- share price and consensus valuation forecast:
Fundamental company analysis:Kintara Therapeutics
Finished products of Kintara Therapeutics Inc

This indicator captures the analysts' consensus forecast for earnings per share (EPS) changes, reflecting market expectations regarding future business profitability. By analyzing the projected trend of net income, investors assess fundamental optimism; for Kintara Therapeutics (KTRA), this is critical, as current quotes already price in the restructuring, and growth now depends exclusively on the success of new clinical trials.

Competitor analysis for Kintara Therapeutics

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|Inhibrx Corp - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec Pharmaceuticals|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Nuvectis NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology Inc.)|BYSI (BeyondSpring) - Expected earnings per share trend next year|BioAtla - Expected earnings per share growth for next year|Projected earnings per share increase next year LIXT (Lixte Biotechnology Holdings, Inc.)|Citius Pharmaceuticals, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year CLRB (Cellectar)|BLRX: Earnings growth forecast for next year|Expected net earnings per share growth next year canfite.com (CANF)|Net earnings per share growth forecast for next year aprea.com|KZIA: Expected earnings per share trend next year|Earnings growth forecast for next year SLXN|Earnings growth forecast for next year NuCana PLC (NCNA)|Net earnings per share growth forecast for next year Chimerix, Inc CMRX|CYCC (Cyclacel) - Net earnings per share change forecast for next year|GTHX: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kronos Bio Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)